Galera Therapeutics upgraded by HC Wainwright & Co. with a new price target
$GRTX
Biotechnology: Pharmaceutical Preparations
Health Care
HC Wainwright & Co. upgraded Galera Therapeutics from Neutral to Buy and set a new price target of $10.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/10/2023 | $6.00 → $0.50 | Overweight → Neutral | Piper Sandler |
| 12/20/2021 | $11.00 → $20.00 | Buy | Citigroup |
| 12/15/2021 | $10.00 | Neutral → Buy | HC Wainwright & Co. |
| 12/15/2021 | $15.00 | Neutral → Buy | BTIG |
| 10/20/2021 | Buy → Neutral | HC Wainwright & Co. | |
| 10/19/2021 | $17.00 → $2.00 | Buy → Underperform | BofA Securities |
| 10/19/2021 | Buy → Neutral | BTIG Research |
Company appoints leading sales, market access and operations executives with decades of experience successfully launching and commercializing new oncology products New Drug Application (NDA) for avasopasem is currently under priority review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee (PDUFA) target date of August 9, 2023 MALVERN, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of accomplished pharmace
MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer (CMO). Dr. Kennedy is a renowned Johns Hopkins-trained surgical oncologist and former Chief of Pancreatic and Hepatobiliary Surgery at Thomas Jefferson University with over 15 years' experience in clinical development and biopharma leadership. He will succeed Jon T. Holmlund, M.D., who will retire at the end of this yea
MALVERN, Pa., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of Mark J. Bachleda, Pharm.D., M.B.A., as Chief Commercial Officer (CCO) and Jennifer Evans Stacey, Esq., as Chief Legal and Compliance Officer (CLCO) and Secretary. Both executives join Galera with over 25 years of leadership experience within the biopharmaceutical industry. "We are thrilled to welcome Mark and Jennifer to Galera at this critical point in the Company's growth," sa
SC 13G/A - Galera Therapeutics, Inc. (0001563577) (Subject)
SC 13G - Galera Therapeutics, Inc. (0001563577) (Subject)
SC 13G/A - Galera Therapeutics, Inc. (0001563577) (Subject)
NT 10-Q - Galera Therapeutics, Inc. (0001563577) (Filer)
8-K - Galera Therapeutics, Inc. (0001563577) (Filer)
25-NSE - Galera Therapeutics, Inc. (0001563577) (Subject)
4/A - Galera Therapeutics, Inc. (0001563577) (Issuer)
4 - Galera Therapeutics, Inc. (0001563577) (Issuer)
4 - Galera Therapeutics, Inc. (0001563577) (Issuer)
3 - Galera Therapeutics, Inc. (0001563577) (Issuer)
4/A - Galera Therapeutics, Inc. (0001563577) (Issuer)
Shares of Science Applications International Corporation (NASDAQ:SAIC) declined 11% to $119.91 following first-quarter results. SAIC reported a 9% revenue decline year over year in the fiscal first quarter of 2025 to $1.847 billion, marginally beating the analyst consensus estimate of $1.844 billion. Adjusted EPS of $1.92 was in line with the analyst consensus estimate, according to data from Benzinga Pro. SAIC shares dipped 11% to $119.91 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Microbot Medical Inc. (NASDAQ:MBOT) jumped 92.5% to $1.9301 after the company received FDA approval to proceed with its pivotal human clinical trial. Bio-Pa
Gainers Structure Therapeutics (NASDAQ:GPCR) stock moved upwards by 71.0% to $58.47 during Monday's regular session. The market value of their outstanding shares is at $2.7 billion. Concord Medical Services (NYSE:CCM) stock rose 55.96% to $0.78. The company's market cap stands at $33.8 million. Microbot Medical (NASDAQ:MBOT) shares moved upwards by 40.79% to $1.41. The market value of their outstanding shares is at $20.2 million. Bio-Path Hldgs (NASDAQ:BPTH) shares moved upwards by 38.0% to $2.84. The market value of their outstanding shares is at $4.7 million. Olema Pharmaceuticals (NASDAQ:OLMA) shares rose 23.45% to $11.95. The market value of their outstanding shares is at $668.4 mil
Galera Therapeutics Inc (NASDAQ:GRTX) shares are trading lower by 34.8% to $0.14 during Monday’s session after the company received a notice from Nasdaq’s Office of General Counsel stating that the Nasdaq Hearings Panel decided to delist the company’s shares due to non-compliance with Nasdaq’s continued listing standards. The company failed to meet the minimum average market value of listed securities, the minimum bid price, and the minimum market value of publicly held shares. As a result, trading of the company’s shares will be suspended on Nasdaq starting June 4, 2024. Galera Therapeutics plans for its shares to be quoted on the OTC Markets Group under the symbol “GRTX” following
Piper Sandler downgraded Galera from Overweight to Neutral and set a new price target of $0.50 from $6.00 previously
Citigroup reiterated coverage of Galera Therapeutics with a rating of Buy and set a new price target of $20.00 from $11.00 previously
HC Wainwright & Co. upgraded Galera Therapeutics from Neutral to Buy and set a new price target of $10.00
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the "Board") has unanimously resolved to adopt a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company's common stock and the Rights Agreement is intended to enable all Galera stockholders to realize the full potential value of their investment in the comp
The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps Galera will take actions to extend its cash runway and continue enrolling its rucosopasem clinical trials Conference call tomorrow, August 10, 2023 at 8:30 a.m. ET MALVERN, Pa., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food an
Corrected topline Phase 3 ROMAN data demonstrate primary endpoint achieved statistical significance in reducing the incidence of radiotherapy-induced severe oral mucositis (p=0.045) Topline results from single-arm Phase 2a trial of avasopasem in Europe in line with the ROMAN trial results Company plans to discuss avasopasem data with the FDA in 2022 Company to host conference call and live audio webcast on Tuesday, December 14 at 8:30 a.m. ET MALVERN, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to
MALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors has approved a Plan of Liquidation and Dissolution (Plan of Dissolution), which provides for the dissolution of the Company under Delaware law, and plans to seek stockholder approval of the Plan of Dissolution at a special meeting of stockholders to be held on or around October 17, 2024. If the Plan of Dissolution is approved by the Company's stockholders, the Company intends t
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the first quarter ended March 31, 2024, and provided recent corporate updates. "Our review of strategic options continues, as we strive to maximize value for our stockholders," said Mel Sorensen, M.D., Galera's President and CEO. "Potential options may include mergers, asset sales, divestiture, licensing arrangements, or other strategic transactions and may encompass a potential development path
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the "Board") has unanimously resolved to adopt a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company's common stock and the Rights Agreement is intended to enable all Galera stockholders to realize the full potential value of their investment in the comp